Whereas the biosimilar industry is under intense pressure from competition, government policies, and slow adoption in certain disease states, there is one area that I think is somewhat more positive: profitability at the present ustekinumab biosimilar discounted pricing. When the adalimumab market opened in January of 2023 discounts off list price increased at a rate … Continue reading Can Biosimilars Survive on These Low WAC Discounts? Remember, not all WACs Are the Same